Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 64.5 kDa.
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
5e5 of anti-GPC3 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human Glypican 3, His Tag (Cat. No. GP3-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
GPC-3298306 | GPC-3298306 | Phase 2 Clinical | National Cancer Center Of Japan | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
BOS-342 | PRS-342; BOS-342; PRS-342/BOS-342 | Phase 2 Clinical | Pieris Pharmaceuticals | Solid tumours; Carcinoma, Hepatocellular | Details |
BOXR-1030 | BOXR-1030 | Phase 2 Clinical | Unum Therapeutics Inc | Liver Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Liposarcoma, Myxoid; Carcinoma, Hepatocellular | Details |
AZD-5851 | AZD-5851; AZD5851 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular | Details |
SAR-444200 | SAR-444200 | Phase 2 Clinical | Sanofi | Solid tumours; Neoplasms | Details |
CAR-GPC3 T-cell (Drum Tower Hospital) | Phase 2 Clinical | Nanjing Drum Tower Hospital | Carcinoma, Hepatocellular | Details | |
GPC3 CAR-T therapy (Hrain Biotechnology) | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details | |
CM-350 | CM-350 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Solid tumours | Details |
GPC3-CAR-T cell therapy(Origincell Medical Technology) | Ori-CAR-001; Ori-C101(OriCell) | Phase 2 Clinical | OriCell Therapeutics Co Ltd | Carcinoma, Hepatocellular | Details |
ECT-204 | JWATM-204; ECT-204 | Phase 2 Clinical | Eureka Therapeutics Inc, Jw Therapeutics (Shanghai) Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Codrituzumab | GC-33; RG-7686; RO-5137382 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details | |
GLYCAR T cell therapy (Baylor College of Medicine) | GLYCAR | Phase 1 Clinical | Baylor College Of Medicine | Rhabdomyosarcoma; Liver Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Wilms Tumor; Liposarcoma; Carcinoma, Hepatocellular; Endodermal Sinus Tumor | Details |
Anti-GPC3 CAR T-cell therapy (Nanjing University) | Phase 1 Clinical | Nanjing University | Carcinoma, Hepatocellular | Details | |
GPC3-CAR-T cell therapy | CSG-GPC-3; CAR-GPC3 T-cell; GPC3-CAR/CSG-GPC3; anti-GPC-3 CAR T; KJgpc3-001; CT-011 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd, Guangdong Zhaotai Invivo Biomedicine Co Ltd | Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details | |
EU-307 | EU307 | Phase 1 Clinical | Eutilex | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
BC-2027 | BC2027; BC-2027 | Phase 1 Clinical | Biocity Biopharmaceutics Co Ltd | Liver Neoplasms; Solid tumours | Details |
JMT-106 | JMT106; JMT-106 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Solid tumours | Details |
GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Solid tumours; Liver Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Mesothelioma; Lung Neoplasms | Details | |
NWRD-06 | NWRD-06; NWRD06 | Phase 1 Clinical | Newish Technology (Beijing) Co Ltd | Carcinoma, Hepatocellular | Details |
GPC3-targeted CAR-T (Peking University) | Phase 1 Clinical | Peking University | Carcinoma, Hepatocellular | Details | |
CAR (hYP7)-T cells (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Liver Neoplasms; Carcinoma, Hepatocellular | Details | |
CT0181 | CT-0181 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Carcinoma, Hepatocellular | Details |
TC-CAR-031 | C-CAR-031; TC-CAR-031; TC-CAR031; C-CAR031 | Phase 1 Clinical | Zhejiang University, Cellular Biomedicine Group Inc | Carcinoma, Hepatocellular | Details |
IM-83 CAR-T cell therapy | IM-83; IM83 | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Liver Neoplasms; Neoplasms; Carcinoma, Hepatocellular | Details |
CT-017 | CT-017 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Carcinoma, Hepatocellular | Details |
JWATM-214 | JWATM-214; JWATM214 | Phase 1 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
TH-012(Bangentai Biomedical) | TH-012 | Phase 1 Clinical | Shandong Bangentai Biomedical Tech Group Co Ltd | Stomach Neoplasms; Pancreatic Neoplasms | Details |
B010-A | B010-A | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Carcinoma, Hepatocellular | Details |
CT-0180 | CT-0180 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Carcinoma, Hepatocellular | Details |
ERY-974 | ERY-974 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
TAK-102 | TAK-102 | Phase 1 Clinical | Noile-Immune Biotech Inc | Solid tumours; Neoplasms | Details |
C-CAR031 CAR T-cell therapy (AbelZeta) | C-CAR031 | Clinical | AbelZeta Pharma Inc | Carcinoma, Hepatocellular | Details |
Anti-GPC3-IRDye800CW | Clinical | Chinese Academy Of Sciences | Details |
This web search service is supported by Google Inc.